Continuous subcutaneous insulin infusion (CSII) is increasingly used as a means of insulin delivery for those with type 1 diabetes, and has recently been endorsed by NICE for this purpose. CSII improves glycaemic control compared to other intensified insulin regimens, with a small decrease in HbA1C and mean blood glucose, and a larger reduction in glucose fluctuation. This improved control is not associated with an increased risk of hypoglycaemia and CSII probably results in significantly lower rates of severe hypoglycaemia. There is no evidence that those using CSII are at increased risk of diabetic ketoacidosis. CSII is uniquely associated with a small risk of application site infection. CSII has a positive impact on quality of life. There is much less evidence concerning the benefits of CSII in reducing microvascular or macrovascular complication rates. Small studies, mostly from the 1980s, show improvements in markers of early nephropathy, retinopathy progression and neuropathy, but the potential long-term impact of CSII has not been proven. Recently CSII has been used in the management of those Br J Diabetes Vasc Dis 2004;4:104—08 with type 2 diabetes but evidence is lacking with regard to the benefits of using it in this group.
Diabetes Control and Complications Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care1995;18:361-76.
2.
Lauritzen T. , Pramming S., Deckert T., Binder C.Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia1983;24:326-9.
3.
Pickup J., Mattock M., Kerry S.Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ2002;324:1-6.
Hanaire-Broutin H., Melki V., Bessieres-Lacombe S., Tauber J.Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care2000;23:1232-5.
6.
Melki V., Renard E., Lassmann-Vague V. et al. Improvement of HbA1c and blood glucose stability in IDDM patients with lispro insulin analogue in external pumps. Diabetes Care1998;21:977-81.
7.
Renner P., Pfützner A., Trautman M., Harzer O., Sauter K., Landraf R.Insulin lispro in CSII: results of a double-blind crossover study. Diabetes1997;46:440-3.
8.
Zinman B., Tildesley H., Chiasson J-L., Tsui E., Strack T.Insulin lispro in CSII: results of a double-blind crossover study. Diabetes1997;46:440-3.
9.
Bode B., Strange P.Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy with type 1 diabetes. Diabetes Care2001;24:69-72.
10.
Bode BW, Steed RD, Davidson PCReduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care1996;19:324-7.
11.
Steindel BS , Roe TR, Costin G., Carlson M., Kaufman FRContinuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diab Res Clin Pract1995; 27:199-204.
Bruttomesso D. , Pianta A., Crazzolara D. et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med2002;19:628-34.
14.
Linkeschova R. , Raoul M., Bott U., Berger M., Spaul M.Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med2002;19:746-51.
15.
Boland EA, Grey M., Oesterle A., Fredrickson L., Tamborlane WVContinuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycaemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care1999;22:1779-84.
16.
De Vries JH, Snoek FJ, Kostense PJ, Masurel N., Heine RJA randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor control. Diabetes Care2002;25:2074-80.
17.
Dcct.Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol1998;116:874-86.
18.
The Kroc Collaborative Study Group.Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. JAMA1988 ;260:36-41.
19.
Olsen T., Richelsen B., Ehlers N., Beck-Nielsen H.Diabetic retinopathy after 3 years treatment with continuous subcutaneous insulin infusion. Arch Ophthalmol Copenh1987 ;65:185-9.
20.
Helve E., Laatikainen L., Merenmies L., Koivisto VAContinuous insulin infusion therapy and retinopathy in patients with type 1 diabetes. Acta Endocrinol Copenh1987;115:313-19.
21.
Bending JJ, Viberti GC, Bilous RW, Keen H.Eight-month correction of hyperglycemia in insulin-dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rates in patients with microalbuminuria. Diabetes1985;34:69-73.
22.
Chiasson JL , Ducros F., Poliquin-Hamet M., Lopez D., Lecavalier L., Hamet P.Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care1984;7:331-7.
23.
Feldt-Rasmussen B., Mathiesen ER, Deckert T.Effect of two years of strict metabolic control on progression of incipient nephropathy in insulindependent diabetes. Lancet1986;2:1300-04.
24.
Beck-Nielsen H., Olesen T., Mogensen CE et al. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Res1990;15:185-90.
25.
Chantelau E. , Wichmann P.Pathological proteinuria in patients with insulin-dependent diabetes mellitus: relation to intensive insulin therapy . Exp Clin Endocrinol1992;99:164-8.
26.
Dahl-Jorgensen K., Hanssen KF, Kierulf P., Bjoro T., Sandvik L., Aagenaes O.Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinol Copenh1988;117:19-25.
27.
Christensen CK, Christiansen JS, Schmitz A., Christensen T., Hermansen K., Mogensen CEEffect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications1987;1:91-5.
28.
Beck-Nielsen H., Richelsen B., Mogensen CE et al. Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care1985;8:585-9.
29.
Bangstad HJ , Osterby R., Dahl-Jorgensen K., Berg KJ, Hartmann A., Hanssen KFImprovement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia1994;37:483-90.
30.
Daubresse JC , Henrivaux P., Bailly A., Lemy C., Duchateau A.Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete Metab1983;9:45-52.
31.
Bertelsmann FW, Heimans JJ, Van Rooy JC, Dankmeijer HF, Visser SL, Van der Veen EAPeripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion . J Neuro Neurosurg Psych1987;50:1337-41.
32.
Boulton AJ, Drury J., Clarke B., Ward JDContinuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care1982;5:386-90.
33.
Kronert K., Hulser J., Luft D., Stetter T., Eggstein M.Effects of continuous subcutaneous insulin infusion and intensified conventional therapy on peripheral and autonomic nerve dysfunction. J Clin End Metab1987;64:1219-23.
34.
Fedele D., Bellavere F., Cardone C., Ferri M., Crepaldi G.Improvement of cardiovascular autonomic reflexes after amelioration of metabolic control in insulin-dependent diabetes subjects with severe autonomic neuropathy . Horm Metab Res1985;17:410-13.
35.
Lawson P., Trayner I., Rosenstock J. et al. The effect of continuous subcutaneous insulin infusion on serum lipids. Diabetes Met1984;10:239-44.
36.
Lormeau B., Aurousseau MH, Valensi P., Paries J., Attali JRHyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism1997;46:1074-9.
37.
Turk Z., Flego I., Kerum G.Platelet aggregation in type 1 diabetes without microvascular disease during continuous subcutaneous insulin infusion. Horm Metab Res1996;28:95-100.
38.
Jennings AM , Lewis KS, Murdoch S., Talbot JF, Bradley C., Ward JDRandomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care1991;14:738-44.
39.
Raskin P., Bode BW, Marks JB et al. Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes. Diabetes Care2003;26:2598-603.
40.
Ilkova H., Glaser B., Tunckale A., Bagriacik N., Cerasi E.Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care1997;20:1353-6.
41.
Della Casa L., del Rio G., Glaser B., Cerasi E.Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. Am J Med1991;90:37S-45S.
42.
Glaser B., Leibovich G., Nesher R., Hartling S., Binder C., Cerasi E.Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol Copenh1988;118:365-73.
43.
Valensi P., Moura I., Le Magoarou M., Paries J., Perret G., Attali JRShort-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabetes Metab1997;23:51-7.
44.
Pouwels MJ, Tack CJ, Hermus AR, Lutterman JATreatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. Diabet Med2003;20:76-9.
